gastric cancer

News

Hengrui gets first OK for a PD-L1/TGF-beta drug for cancer

Hengrui has achieved a milestone in oncology as retlirafusp alfa is approved in China, its first world market, for gastric cancer.

News

Takeda builds in cancer with monster $11.4bn Innovent deal

Takeda has partnered with China's Innovent for a pair of late-stage cancer therapies, in a deal that includes an upfront payment of $1.2bn.

News

Amgen's Five Prime takeover delivers gastric cancer win

Four years after buying Five Prime for $1.9bn, Amgen has promising phase 3 results with a gastric cancer drug that was the focal point for the deal.

Oncology

ASCO 2025: Building a stronger future in cancer care with a ...

From attending key oral sessions, clinical science symposiums and poster presentations to the simple pleasures of chatting with colleagues during coffee breaks, we left the

News

ASCO 25: Enhertu bids for earlier use in HER2+ breast cancer

AstraZeneca and Daiichi Sankyo have revealed the data they hope will move Enhertu into frontline therapy for HER2-positive advanced breast cancer.

News

Astellas adds to claudin clout with $1.3bn+ Evopoint deal

Astellas was the first company to bring a drug against the claudin target CLDN18.2 to market, and has now added another to its cancer pipeline.

Hengrui gets first OK for a PD-L1/TGF-beta drug for cancer

Takeda builds in cancer with monster $11.4bn Innovent deal

Amgen's Five Prime takeover delivers gastric cancer win

ASCO 2025: Building a stronger future in cancer care with a ...

ASCO 25: Enhertu bids for earlier use in HER2+ breast cancer

Astellas adds to claudin clout with $1.3bn+ Evopoint deal

NHS "isn't delivering equitable care for rare diseases"

Using AI-driven synthetic personas to take your insights fur...

gastric cancer

Editor's Picks